THIRD QUARTER 2008 FINANCIAL RESULTS
Confirmation of Annual and Special General Meeting of Shareholders
VANCOUVER, Oct. 28 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, will host a conference call discussing its financial results for the third quarter ended September 30, 2008 on Thursday, November 6, 2008 at 11:00 AM ET (8:00 AM Pacific).
The Company's Annual and Special General Meeting of Shareholders is
confirmed for Thursday, October 30, 2008 at 11:30 AM ET (8:30 AM Pacific).
Due to the proximity of the earnings conference call, there will be no
management update at the Annual and Special General Meeting of
Shareholders; and therefore, the meeting will not be made available via
webcast or conference call.
Dial information for the earnings call on November 6, 2008 is as follows:
North America (toll-free): (866) 383-7998
International: (617) 597-5329
Enter passcode: 11247654
A live webcast of the earnings conference call will be available to all interested parties through Angiotech's website at http://www.angiotech.com in the Investor Relations section.
A press release announcing Angiotech's financial results will be issued prior to the conference call on November 6 at approximately 8:00 AM ET (5:00 AM Pacific).
A replay archive of the conference call will be available until
November 13, 2008.
Replay information is as follows:
North America: (888) 286-8010
International: (617) 801-6888
Enter passcode: 75181409
About Angiotech Pharmaceuticals
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP) please visit our website at http://www.angiotech.com.
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved